– USA, CA / IRELAND, Dublin – ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Rekha Hemrajani to its Board of Directors.
With more than 20 years of biopharmaceutical industry experience, Ms. Hemrajani’s expertise is rooted in corporate strategy, business development, finance and operations.
“Rekha brings an impressive background and perspective in her numerous leadership roles developing successful biopharma companies,” said Corey Goodman, Ph.D., Executive Chairman. “We welcome Rekha and her strong financial, operations and business development experience, which will be instrumental for our company’s growth.”
About Rekha Hemrajani
Ms. Hemrajani currently serves as Board Member, Chair of Audit Committee at Adverum Biotechnologies. She most recently served as President and CEO at Aravive. She has served as COO and CFO at Arcus Biosciences; COO at FLX Bio (now RAPT Therapeutics); CFO, SVP of Business and Financial Operations at 3-V Biosciences (now Sagimet Biosciences); VP, Head of Licensing and M&A at Onyx Pharmaceuticals (acquired by Amgen); and VP of Business Development at Exelixis. She also serves as a member of the Investment Advisory Board of the Monroe Brown Seed Fund at the University of Michigan.
“I’m pleased to join the distinguished Board at ALX and to leverage my experience and relationships in advancing the Company’s strategy of developing ALX148 across a range of hematologic malignancies and solid tumors in combination with a number of leading anti-cancer agents,” said Ms. Hemrajani.
Before launching an investment banking career at Credit Suisse and Lehman Brothers, Ms. Hemrajani earned an M.B.A., Finance and Marketing at Northwestern University Kellogg School of Management and a Bachelor of Economics, Computer Science at the University of Michigan.
About ALX Oncology
ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next-generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain. ALX148 has demonstrated promising clinical activity across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to advance ALX148 into clinical development for the treatment of myelodysplastic syndromes and to continue clinical development for the treatment of a range of solid tumor indications.
For more information: http://alxoncology.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.